https://www.selleckchem.com/pr....oducts/3-methyladeni
To evaluate amyloid-β deposition with F-florbetaben (FB PET imaging against C-PIB PET in cognitive normal controls (NC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) patients. We recruited 45 subjects (15 in each group of NC, MCI, and mild/moderate AD) who had undergone dynamic F-FBB amyloid PET imaging. For comparison study, 17 participants, including six NC, five MCI, and six AD patients, also underwent C-PIB PET imaging on separate days. Standardized uptake value ratios (SUVR) were calculated using the cere
Like
Comment
Share
